Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Conditions: Carcinoma, Non-Small-Cell Lung Interventions: Drug: Amivantamab; Drug: Lazertinib; Drug: Doxycycline; Drug: Minocycline; Drug: Clindamycin; Drug: Chlorhexidine; Other: Noncomedogenic skin moisturizer Sponsors: Janssen Research& Development, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Chlorhexidine | Clindamycin | Dermatology | Doxycycline | Lung Cancer | Minocycline | Non-Small Cell Lung Cancer | Research | Skin | Solodyn